

ASTRAZENECA PLC
Form 6-K
May 01, 2015

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of May 2015
Commission File Number: 001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____

Transaction by Persons Discharging Managerial Responsibilities

Disclosure Rule DTR 3.1.4

Edgar Filing: ASTRAZENECA PLC - Form 6-K

The following individuals, who are all Directors of the Company, have notified us that they have purchased AstraZeneca PLC Ordinary Shares of \$0.25 each or AstraZeneca American Depositary Shares (ADSs).

One AstraZeneca ADS equals one AstraZeneca PLC Ordinary Share of \$0.25.

| Name of Director | Date of notification | Date of purchase | Number of shares purchased | Purchase price |
|------------------------|----------------------|------------------|----------------------------|----------------|
| Cori Bargmann | 1 May 2015 | 29 April 2015 | 700 | \$69.21 |
| Ann Cairns | 1 May 2015 | 30 April 2015 | 1,100 | 4455p |
| Jean-Philippe Courtois | 29 April 2015 | 28 April 2015 | 2,500 | 4536p |

A C N Kemp
Company Secretary
1 May 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 01 May 2015

By: /s/ Adrian Kemp
Name: Adrian Kemp
Title: Company Secretary